Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance

NCT04245085 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.

NCT NCT04245085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04245085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance
Lead sponsor
ETOP IBCSG Partners Foundation
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2020
Completion date
July 22, 2024
Enrollment
95 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

egfrmutant stage iiib/c or iv non-squamous nsclc